Quest Laboratories Limited (NSE SME)
May 15, 2024 - May 17, 2024
| Price | ₹93 - ₹97 |
| Premium | ₹80 |
|---|---|
| Lot size | 1200 |
| Allotment | May 21, 2024 |
| Listing | May 23, 2024 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 1200 | 116400 | 1249 |
| HNI | 2 | 2400 | 232800 | 546 |
Last updated on 17-May-2024 17:03:03
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 831600 | 47571600 | 57.2 |
| NIB | 655200 | 120852000 | 184.45 |
| RETAIL | 1498800 | 86370000 | 57.63 |
| Total | 2985600 | 254793600 | 85.34 |
| Retail Apps | 71975 | © IPO Premium | |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹24.02 | @8% ₹27.45 | @9% ₹30.88 | @10% ₹34.31 | @11% ₹37.74 | @12% ₹41.18 |
Anchor Details
| Name of Anchor | No. of Shares | % Portion | Amount (cr) |
|---|---|---|---|
| Persistent Growth Fund - Varsu India Growth Story Scheme - 1 | 618000 | 50.00% | 5.99 |
| Craft Emerging Market Fund PCC - Citadel Capital Fund | 387600 | 31.36% | 3.76 |
| Rajsthan Global Securities Private Limited | 127200 | 10.29% | 1.23 |
| TGISME Fund | 103200 | 8.35% | 1.00 |
| Total | 1236000 | 100.00% | 11.99 |
IPO Reservations
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 33.68% | 1498800 |
| NII (HNI) | 14.72% | 655200 |
| Anchor | 27.78% | 1236000 |
| QIB | 18.69% | 831600 |
| Market Maker | 5.12% | 228000 |
| Total | 100.00% | 4449600 |
Quest Laboratories IPO Details
| Issue Size | 4,449,600 shares (aggregating up to ₹43.16 Cr) |
| Fresh Issue | 4,449,600 shares (aggregating up to ₹43.16 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 11,937,600 |
| Share holding post issue | 16,387,200 |
| Market Maker portion | 228,000 shares Rikhav Securities |
Key Performance Indicator
| KPI | Dec-23 | Mar-23 | Mar-22 |
|---|---|---|---|
| ROE | 34.03% | 40.20% | 51.69% |
| RONW | 34.03% | 33.47% | 41.08% |
| D/E | 0.20 | 0.27 | 0.31 |
| EPS (Diluted) | 7.18 | 4.66 | 3.81 |
| P/BV | 4.59 | ||
| P/E Pre IPO | 23.03 |
Company Financials
Quest Laboratories Limited Financial Information (Restated)
Quest Laboratories Limited's revenue increased by 3.9% and profit after tax (PAT) rose by 22.5% between the financial year ending with March 31, 2023 and March 31, 2022.
| Period | Dec 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| Assets | 5,869.09 | 4,664.72 | 3,479.86 | 1,839.63 |
| Revenue | 6,217.83 | 6,186.60 | 5,954.20 | 3,043.55 |
| Profit | 774.93 | 502.85 | 410.50 | 65.50 |
| Net Worth | 2,277.15 | 1,502.21 | 999.38 | 588.84 |
| Reserves | 1,198.39 | 1,394.33 | 891.50 | 480.96 |
| Borrowing | 460.66 | 409.69 | 312.54 | 304.03 |
| Amount in ₹ Lakhs | ||||
About Company
Established in June 1998, Quest Laboratories Limited is a distinguished pharmaceutical company renowned for manufacturing a diverse range of medical solutions including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, and antidepressants. Operating predominantly within the domestic market across twelve states and two union territories, encompassing regions such as Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal, Gujarat, Telangana, Haryana, and Bihar, the company has strategically positioned itself as a key player in the pharmaceutical landscape. Headquartered in Dhar, Madhya Pradesh, Quest Laboratories boasts state-of-the-art manufacturing facilities adhering to stringent WHO Schedule M GMP and GLP standards, alongside ISO/IEC 17025:2017 and ISO 9001:2015 certifications, ensuring the highest quality standards. With a dedicated team of 83 professionals overseeing various facets of manufacturing operations, including production, quality control, technical and engineering support, inventory management, administration, accounting, as well as storage, packing, and dispatch, Quest Laboratories is committed to delivering excellence across all its endeavors.
Strength Factors
Multi-Product Capability: The company's diverse product range showcases its versatility and ability to cater to various healthcare needs, providing resilience against market fluctuations and expanding growth opportunities.
Revenue from Government Institutions: Securing revenue from government institutions highlights the company's reliability and established reputation, offering stability and long-term financial sustainability.
Robust Product Portfolio: With a comprehensive product portfolio spanning multiple therapeutic areas, the company enjoys a competitive advantage, driving market penetration and ensuring continued relevance in the pharmaceutical industry.
Risk Factors
Legal Risks: Ongoing litigation poses a significant risk, potentially impacting the company's business, reputation, and financial performance. Adverse outcomes in legal proceedings, particularly those involving the promoter, could lead to operational disruptions and financial liabilities.
Promoter's Legal Issues: The promoter's involvement in legal matters, including imprisonment and ongoing appeals, introduces uncertainty regarding the company's future. Any adverse decisions in these cases may directly affect the company's operations and stability.
Quality Control Concerns: Manufacturing or quality control issues pose a threat to the company's reputation for delivering high-quality products. Any lapses in quality could lead to litigation, regulatory penalties, and reputational damage, ultimately impacting the company's financial results and market standing.
Quest Laboratories IPO Lead Manager(s)
- Shreni Shares Limited
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/ipo_status.html